A look at Exact Sciences Corporation’s acquisition by Abbott: review EXAS revenue growth, margins, and CRC/MRD screening ...
Nationwide access enabled through Quest Diagnostics' 7,000 patient access sites The Cancerguard test will be delivered through Exact Sciences’ expansive commercial and operational infrastructure, ...
New evidence shows multi-biomarker class approach improved cancer detection, including in earlier stages when treatment may be more effective A new study demonstrates the ability of a multi-biomarker ...
Exact SciencesEXAS stock crashed to a three-year low Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer test. The company already developed a blood-based ...
Primary study sites Baylor Scott & White Health in Texas and Endeavor Health in Illinois aim to enroll up to 25,000 patients from diverse backgrounds, assessing the impact of MCED testing on clinical ...
On Friday, the FDA approved Exact Sciences Corp.’s (NASDAQ:EXAS) Cologuard Plus test, the company’s next-generation multi-target stool DNA test. The Cologuard Plus test is now approved for adults ages ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback